If you are seeking a reliable solution to prevent hypersensitivity reactions to abacavir in HIV-infected patients, the Viennalab HLA-B5701 RealFast™ Assay offers an efficient and accurate method to identify individuals at risk. By determining the presence or absence of the HLA-B*57:01 allele, this real-time PCR test plays a crucial role in patient care, helping to prevent serious adverse reactions associated with abacavir therapy. This kit is an essential tool for clinicians aiming to make informed and safe treatment decisions.

Importance of HLA-B5701 Screening

Abacavir is a widely used antiretroviral drug in combination therapy for treating HIV-1 infections. While effective, it is known to cause hypersensitivity reactions (HSR) in patients carrying the HLA-B*57:01 allele. Between 5% and 8% of Caucasian HIV-1 patients who are HLA-B57:01 positive develop such reactions, which can appear within the first six weeks of treatment. These hypersensitivity reactions often present with symptoms such as rash, fever, gastrointestinal issues, and respiratory complications. If abacavir-induced hypersensitivity is not recognized early, re-exposure to the drug can lead to life-threatening conditions. Therefore, identifying **HLA-B57:01 positive patients** before beginning abacavir therapy is essential for ensuring patient safety.

The Viennalab HLA-B5701 RealFast™ Assay offers a simple, fast, and highly accurate method for genetic risk stratification. By screening patients for this allele, clinicians can reduce the incidence of abacavir hypersensitivity reactions, thus improving patient outcomes and ensuring the safe administration of HIV treatment.

The assay is validated to ensure high specificity and does not cross-react with similar variants such as HLA-B*57:02 or HLA-B*57:03, ensuring precise results. The assay delivers rapid results that help guide clinical decisions, especially in cases where timely intervention is crucial for preventing hypersensitivity reactions.

Conclusion

The Viennalab HLA-B5701 RealFast™ Assay is an indispensable tool for clinicians involved in the care of HIV-infected patients. By accurately detecting the HLA-B*57:01 allele, this assay helps prevent serious and potentially life-threatening hypersensitivity reactions to abacavir. With its ease of use, rapid turnaround time, and high specificity, the RealFast™ assay ensures that patients can be safely treated with appropriate therapies.